About Perfuse Therapeutics
Perfuse Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2018 by Sevgi Gurkan, and was acquired by Bayer in May 2026. Developer of therapies to treat eye disorders. Its chief executive, as recorded, is Sevgi Gurkan. Perfuse Therapeutics offers products and services including Endothelin Antagonist. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is Perfuse Therapeutics, Inc. Its competitors include Bausch & Lomb, Katalyst Surgical and Katena; 2 of its 3 listed competitors have raised funding.
Company details
Perfuse Therapeutics was founded in 2018 in San Francisco, United States, within the biotechnology sector. Focus is placed on developing treatments for eye disorders, including glaucoma and retinal diseases. A proprietary technology is employed to enhance retinal perfusion, targeting improved outcomes in these conditions. Operations center on therapeutic innovation for ocular health applications.
- Headquarters San Francisco, United States
- Founders Sevgi Gurkan
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website perfusetherapeutics.com
- Social LinkedIn
- Acquired by Bayer (May 2026)
- Legal Name Perfuse Therapeutics, Inc
Products & Services of Perfuse Therapeutics
Perfuse Therapeutics offers a comprehensive portfolio of products and services, including Endothelin Antagonist.
Improves blood flow to retina to treat glaucoma and diabetic retinopathy.
Funding Insights of Perfuse Therapeutics
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Perfuse Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | Series A | – | Access Industries | – |
2 investors in total: 2 institutional.
Investors in Perfuse Therapeutics
Perfuse Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer and Access Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and holding company controlled by Len Blavatnik | accessindustries.com | New York, United States | ||
Life science solutions for healthcare and agriculture are delivered. | 1863 | bayer.com | Leverkusen, Germany |
Investor details for Perfuse Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Perfuse Therapeutics
9 people are tracked at Perfuse Therapeutics (5 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Sevgi Gurkan | Founder & CEO | Leadership |
Phillip Lai | Chief Medical Officer | Leadership |
Angela Glendenning | Vice President Of Product Development | Leadership |
Karen Brennan | Vice President, Pharmaceutical Development | Leadership |
Michelle Chen | Vice President, Head Of Clinical Development | Leadership |
Maria Zaretskaia, M.D. | Principal Scientist | Team |
Andrew Melie | Analytical Scientist | Team |
Christopher Romeo | Principal Scientist, Device And Formulation | Team |
Heather Schmitt | Clinical Development Scientist | Team |
Complete people profiles for Perfuse Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Perfuse Therapeutics
3 dated milestones of Perfuse Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Perfuse Therapeutics is founded.
- Funding First funding round.
- Exit Acquired by Bayer.
Competitors of Perfuse Therapeutics
Perfuse Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Bausch & Lomb, Katalyst Surgical and Katena.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bausch.com | 1853 | Bridgewater, United States | 1,681 | Ophthalmic pharmaceuticals and instruments are developed for eye care. | ||
| katalystsurgical.com | 2010 | St. Louis, United States | $340,000 | 53 | Titanium ophthalmic surgical instruments are manufactured and repaired. | |
| katena.com | 1975 | Tampa, United States | $7.5M | 145 | Ophthalmic surgical instrument manufacturer |
Detailed competitors of Perfuse Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Perfuse Therapeutics
The website of Perfuse Therapeutics (perfusetherapeutics.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 26.5% vs previous month
Top companies in Ophthalmology
3 companies that operate in the same segment as Perfuse Therapeutics (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 24.69 B | 25,941 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Perfuse Therapeutics
Complete news archive for Perfuse Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perfuse Therapeutics
Perfuse Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Perfuse Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Sevgi Gurkan is the CEO of Perfuse Therapeutics, as recorded in our data. They have also founded this company.
Perfuse Therapeutics was founded in 2018 in San Francisco, United States, within the biotechnology sector. Focus is placed on developing treatments for eye disorders, including glaucoma and retinal diseases. A proprietary technology is employed to enhance retinal perfusion, targeting improved outcomes in these conditions. Operations center on therapeutic innovation for ocular health applications.
Perfuse Therapeutics's top competitors include Bausch & Lomb, Katalyst Surgical and Katena.
Perfuse Therapeutics offers Endothelin Antagonist.
Perfuse Therapeutics has 2 investors. Key investors include Bayer, and Access Industries.
Perfuse Therapeutics operates through Perfuse Therapeutics, Inc.
Yes. Perfuse Therapeutics was acquired by Bayer in May 2026.